Holen Sie sich die Stockscreener-App
0.5403
2.82%
-0.0157
Handel nachbörslich:
.52
-0.0203
-3.76%
Schlusskurs vom Vortag:
$0.556
Offen:
$0.56
24-Stunden-Volumen:
46,006
Relative Volume:
0.41
Marktkapitalisierung:
$13.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.56M
KGV:
-0.8312
EPS:
-0.65
Netto-Cashflow:
$-22.29M
1W Leistung:
-3.40%
1M Leistung:
-9.95%
6M Leistung:
-44.84%
1J Leistung:
-80.72%
1-Tages-Spanne:
$0.5207
$0.5618
1-Wochen-Bereich:
$0.52
$0.5779
52-Wochen-Spanne:
$0.477
$4.99
BiomX Inc Stock (PHGE) Company Profile
Firmenname
BiomX Inc
Sektor
Branche
Telefon
972 7 23942377
Adresse
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Vergleichen Sie PHGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.5403 | 13.49M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-15 | Eingeleitet | Ladenburg Thalmann | Buy |
BiomX Inc Aktie (PHGE) Neueste Nachrichten
HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World
Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com Australia
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX reports progress in diabetic ulcer treatment - Investing.com India
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan
Phage Therapy Market Know the Scope and Trends - openPR
BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World
BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus
BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
Earnings Scheduled For March 25, 2025 - Benzinga
BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire
BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
BiomX’s $12 Million Financing - Global Legal Chronicle
BiomX Inc. secures $12 million from recent offerings - Investing.com India
Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today
BiomX Announces $12M Funding for BX004 Study - TipRanks
BiomX announces series of financings for aggregate gross proceeds of $12M - MSN
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire
Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan
BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World
Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Finanzdaten der BiomX Inc-Aktie (PHGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):